| 
Results for ambrisentan. Search took 0.01 seconds.
Letairis™ (ambrisentan), FDA-Approved for Pulmonary Arterial Hypertension
in Straightfromthedoc, on June 17, 2007
... Manufactured by Gilead Sciences, Inc. , Letairis™ (ambrisentan) has recently been approved by the FDA for the treatment of pulmonary arterial hypertension .
Pulmonary arterial hypertensi...
Biotech Companies Announcing Public Offering of Common Stocks
in The Biotech Weblog, on September 19, 2005
...stock at $23.25 per share. Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the tr...